Evolus

Yahoo Finance • 7 months ago

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 10 months ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story

Yahoo Finance • last year

"Extra-Strength" 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

"Extra-strength" 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment 40U results indicate a similar safety p... Full story

Yahoo Finance • 2 years ago

Q4 2022 Evolus Inc Earnings Call

Participants David Moatazedi; President, CEO & Director; Evolus, Inc. David K. Erickson; VP of IR; Evolus, Inc. Rui Avelar; Chief Medical Officer and Head of Research & Development; Evolus, Inc. Sandra Beaver; CFO; Evolus, Inc. Annabe... Full story

Yahoo Finance • 2 years ago

Evolus to Participate in the Barclays Global Healthcare Conference

NEWPORT BEACH, Calif., February 28, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its manageme... Full story

Yahoo Finance • 2 years ago

Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress

Oral presentation for longer duration formulation on Saturday, January 28, 2023 Investor webcast to discuss findings on Monday, January 30, 2023 NEWPORT BEACH, Calif., January 23, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a perf... Full story

Yahoo Finance • 2 years ago

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

Results demonstrated percentages of male responders treated with Jeuveau® achieved approximately 10% higher results across all visits NEWPORT BEACH, Calif., August 24, 2022--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beau... Full story

Yahoo Finance • 2 years ago

Evolus Reports First Quarter 2022 Results and Provides Business Update

Q1 2022 Net Revenue of $33.9 Million, Up 177% from Q1 2021 Now Guiding to Upper End of Full-Year 2022 Net Revenue of $143 to $150 Million Reiterating Full-Year non-GAAP Operating Expense Guidance Strong Cash Position of $106.7 Million Expe... Full story

Yahoo Finance • 3 years ago

Kaskela Law LLC Announces Stockholder Investigation of Evolus, Inc. (EOLS) and Encourages Long-Term EOLS Stockholders to Contact the Firm

PHILADELPHIA, April 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) on behalf of the Company’s long-term shareholders. Evolus stockholders who purch... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evolus, Inc. (NASDAQ: EOLS) and Encourages Long-Term EOLS Shareholders to Contact the Firm

PHILADELPHIA, March 29, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) on behalf of the Company’s long-term shareholders. Recently an amended securitie... Full story